
Dyne Therapeutics, Inc. (NASDAQ:DYN – Free Report) – Investment analysts at HC Wainwright lowered their FY2026 EPS estimates for Dyne Therapeutics in a note issued to investors on Friday, November 6th. HC Wainwright analyst A. Ghosh now expects that the company will earn ($3.83) per share for the year, down from their prior forecast of ($3.82). HC Wainwright currently has a “Buy” rating and a $32.00 target price on the stock. The consensus estimate for Dyne Therapeutics’ current full-year earnings is ($3.81) per share. HC Wainwright also issued estimates for Dyne Therapeutics’ Q4 2026 earnings at ($0.95) EPS, Q1 2027 earnings at ($0.91) EPS, FY2027 earnings at ($3.42) EPS, FY2028 earnings at ($2.15) EPS and FY2029 earnings at ($0.84) EPS.
Several other research analysts have also recently weighed in on DYN. Raymond James Financial restated a “strong-buy” rating and set a $37.00 target price on shares of Dyne Therapeutics in a report on Tuesday, September 8th. Wall Street Zen cut Dyne Therapeutics from a “sell” rating to a “strong sell” rating in a report on Saturday, August 1st. JPMorgan Chase & Co. downgraded Dyne Therapeutics from a “neutral” rating to an “underweight” rating and reduced their price objective for the stock from $17.00 to $10.00 in a research report on Wednesday, September 9th. Piper Sandler reiterated an “overweight” rating and set a $47.00 price objective on shares of Dyne Therapeutics in a research report on Tuesday, September 29th. Finally, Oppenheimer lowered Dyne Therapeutics from an “outperform” rating to a “market perform” rating and lowered their price objective for the stock from $40.00 to $15.00 in a research note on Wednesday, October 28th. One analyst has rated the stock with a Strong Buy rating, eleven have issued a Buy rating, two have given a Hold rating and two have given a Sell rating to the stock. According to data from MarketBeat.com, Dyne Therapeutics currently has a consensus rating of “Moderate Buy” and an average price target of $31.29.
Dyne Therapeutics Stock Up 0.4%
Shares of NASDAQ DYN opened at $17.99 on Tuesday. Dyne Therapeutics has a 12-month low of $14.00 and a 12-month high of $27.31. The stock has a market cap of $3.37 billion, a PE ratio of -4.96 and a beta of 1.22. The company has a current ratio of 12.99, a quick ratio of 12.99 and a debt-to-equity ratio of 0.21. The company has a 50-day moving average of $17.28 and a 200 day moving average of $19.34.
Dyne Therapeutics (NASDAQ:DYN – Get Free Report) last posted its quarterly earnings results on Thursday, November 5th. The company reported ($1.06) earnings per share for the quarter, missing the consensus estimate of ($0.91) by ($0.15). During the same period in the previous year, the firm earned ($0.76) EPS.
Institutional Trading of Dyne Therapeutics
Several institutional investors and hedge funds have recently bought and sold shares of DYN. Aegis Wealth Management LLC boosted its stake in Dyne Therapeutics by 6.7% during the third quarter. Aegis Wealth Management LLC now owns 160,030 shares of the company’s stock worth $2,578,000 after buying an additional 10,000 shares during the period. Cibc World Market Inc. increased its position in shares of Dyne Therapeutics by 13.8% during the third quarter. Cibc World Market Inc. now owns 86,243 shares of the company’s stock valued at $1,389,000 after acquiring an additional 10,460 shares during the last quarter. Teachers Retirement System of The State of Kentucky purchased a new stake in shares of Dyne Therapeutics in the 3rd quarter valued at approximately $646,000. Russell Investments Group Ltd. raised its stake in shares of Dyne Therapeutics by 141.8% in the 3rd quarter. Russell Investments Group Ltd. now owns 255,190 shares of the company’s stock valued at $4,111,000 after acquiring an additional 149,637 shares during the period. Finally, Pictet Asset Management Holding SA raised its stake in shares of Dyne Therapeutics by 7.4% in the 3rd quarter. Pictet Asset Management Holding SA now owns 20,805 shares of the company’s stock valued at $335,000 after acquiring an additional 1,433 shares during the period. 96.68% of the stock is currently owned by hedge funds and other institutional investors.
Insiders Place Their Bets
In other Dyne Therapeutics news, insider Douglas Kerr sold 3,745 shares of Dyne Therapeutics stock in a transaction on Friday, September 4th. The stock was sold at an average price of $24.35, for a total value of $91,190.75. Following the sale, the insider owned 163,854 shares in the company, valued at $3,989,844.90. The trade was a 2.23% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CEO John Cox sold 5,658 shares of the company’s stock in a transaction on Tuesday, September 8th. The shares were sold at an average price of $18.88, for a total value of $106,823.04. Following the completion of the transaction, the chief executive officer directly owned 357,507 shares in the company, valued at approximately $6,749,732.16. This trade represents a 1.56% decrease in their position. The disclosure for this sale is available in the SEC filing. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders sold 2,172,294 shares of company stock worth $54,260,677 in the last three months. 9.46% of the stock is owned by insiders.
Dyne Therapeutics News Roundup
Here’s some of the latest news about DYN:
- Positive Sentiment: HC Wainwright maintained its Buy rating and $32 target, well above the share price cited in the background information. It also raised its Q4 2026 EPS estimate to a loss of $0.95 per share from a loss of $1.01. Analyst coverage
- Neutral Sentiment: Dyne said management will participate in an upcoming investor conference. The announcement may provide an opportunity for updates, but no new company information was disclosed. Investor conference announcement
- Negative Sentiment: HC Wainwright trimmed its EPS forecasts for fiscal 2027–2029, indicating somewhat higher expected losses in those years. Separately, PepGen reported encouraging splicing results for a DM1 drug candidate, a potential competitive development in a disease area relevant to Dyne; the report does not establish a direct impact on Dyne’s programs. PepGen article
Dyne Therapeutics Company Profile
Dyne Therapeutics is a clinical-stage biotechnology company developing therapies for genetically driven muscle diseases. Its research uses the FORCE platform, which is designed to deliver oligonucleotide medicines to muscle tissue. The company’s programs include DYNE-101 for myotonic dystrophy type 1 and DYNE-251 for Duchenne muscular dystrophy in patients whose genetic mutations are amenable to exon 51 skipping. Dyne has also pursued a program for facioscapulohumeral muscular dystrophy. Its therapies remain in development, and the company does not have an approved product.
Read More
- Five stocks we like better than Dyne Therapeutics
- Keeping AI Cool: AAON Rides the AI Heatwave to Record Growth
- AST SpaceMobile Has a New Rocket Plan, But Its Cash-Burn Problem Isn’t Going Away
- Powering Up the Moon: Redwire’s $40 Million NASA Award
- Can Constellation Energy’s Contracts Power a Stock Rebound?
Receive News & Ratings for Dyne Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dyne Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
